Pfizer CentreOne Redefines Developer-Manufacturer Paradigm Through Strategic Partnerships

Strategic Insights -

Pfizer CentreOne, a leading contract development and manufacturing organization (CDMO), is shifting its focus from a traditional "transactional function" to stronger long-term partnerships with a select group of customers. Jim Donovan, the company's vice president, emphasized the importance of building credibility and growing partnerships beyond single assets to encompass broader portfolios from repeat customers. By leveraging lessons learned from the COVID-19 pandemic, Pfizer CentreOne aims to become a "little bit exclusive" by focusing on a smaller number of clients and building deeper relationships.

Key Takeaways:

  • Pfizer CentreOne is pivoting from a traditional "transactional function" to stronger long-term partnerships with a select group of customers.
  • The company aims to be "a little bit exclusive" by focusing on a smaller number of clients and building deeper relationships.
  • Pfizer CentreOne conducts the bulk of its (OSD) manufacturing across three Pfizer sites in Italy, Germany, and Ireland.
  • Sterile injectable manufacturing primarily takes place at facilities in Spain, Belgium, Sweden, Croatia, and Kansas in the U.S.
  • The company is eyeing the GLP-1 space for potential work, particularly in oral incretin medicines for diabetes and weight loss.
  • Pfizer CentreOne has developed "light speed behaviors" retained from the COVID-19 pandemic, prioritizing time-to-market and time-to-file.

Statistics:

  • Pfizer CentreOne operates within a manufacturing network spanning 35 sites globally.
  • The company conducts (OSD) manufacturing primarily at three Pfizer sites in Italy, Germany, and Ireland.
  • Sterile injectable manufacturing takes place at facilities in Spain, Belgium, Sweden, Croatia, and Kansas in the U.S.
  • Pfizer CentreOne is targeting the GLP-1 space, with an estimated global market value reaching $173.5 billion by 2031.

Sources:

  • Fierce Pharma, Interview with Jim Donovan, Vice President at Pfizer CentreOne
  • GlobalData, Market Research on the GLP-1 Market